Johnson & Johnson (JNJ) ICOTYDE Update Keeps Fair Value In Focus

Johnson & Johnson (JNJ) just reported fresh two year Phase 3 ICONIC-TOTAL data for ICOTYDE in plaque psoriasis, giving investors another clinical milestone to weigh against the recent pullback in the stock.

Despite the new ICOTYDE data, Johnson & Johnson’s recent share price has pulled back, with the stock down 7% over the past week and 8% over the last month. That short term softness sits against a stronger backdrop, including a 1 year total shareholder return of 37.45% and an 81.49% total shareholder return over 5 years. This suggests momentum has been building over longer horizons even as the latest clinical headlines and reassessment of risk have taken some heat out of the recent move.

Capitalize on Johnson & Johnson’s clinical momentum by scanning a curated pool of healthcare leaders in our 33 healthcare AI stocks that could be setting up their next move.

Bulls point to Johnson & Johnson’s ICOTYDE progress and long run returns. Bears focus on the pullback and pipeline risk. As you weigh valuation next, which side do the current numbers actually support?

Most Popular Narrative: 6.5% Undervalued

Compared with Johnson & Johnson’s last close at $252.93, the most followed narrative pegs fair value at $270.59. This implies a modest valuation gap built on detailed assumptions about earnings, margins, and policy risk.

The analysts have a consensus price target of $270.59 for Johnson & Johnson based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $305.0, and the most bearish reporting a price target of just $190.0.

See why 506 investors see Johnson & Johnson as 7% undervalued.

Result: Fair Value of $270.59 (UNDERVALUED)

Still, the narrative can crack if talc litigation outcomes are harsher than expected or if STELARA’s loss of exclusivity hits Johnson & Johnson’s margins harder.

Find out about the key risks to this Johnson & Johnson narrative.

Next Steps

Mixed feelings on Johnson & Johnson after the Phase 3 update and recent pullback are understandable. Move quickly, test the data yourself, and weigh both the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Johnson & Johnson?

If Johnson & Johnson has sharpened your interest, do not stop here. Broaden your watchlist with fresh ideas that match different risk and income goals.

• Target dependable income streams by scanning a focused set of resilient payers in our 7 dividend fortresses.
• Hunt for potential mispricings by running a quick pass across our curated pool of quality candidates in the 27 high quality undervalued stocks.
• Protect your downside risk by filtering for sturdier balance sheets and durable fundamentals in the list of solid balance sheet and fundamentals (25 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com